Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
2.32
Dollar change
+0.14
Percentage change
6.42
%
Index- P/E- EPS (ttm)-5.82 Insider Own51.12% Shs Outstand21.93M Perf Week15.42%
Market Cap51.05M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.76M Perf Month49.68%
Income-112.83M PEG- EPS next Q- Inst Own11.33% Short Float8.68% Perf Quarter-17.44%
Sales42.69M P/S1.20 EPS this Y- Inst Trans0.93% Short Ratio0.89 Perf Half Y-28.40%
Book/sh1.27 P/B1.83 EPS next Y- ROA-59.09% Short Interest0.93M Perf Year9.23%
Cash/sh0.02 P/C108.62 EPS next 5Y- ROE-154.23% 52W Range1.30 - 7.97 Perf YTD-6.22%
Dividend Est.- P/FCF- EPS past 5Y-718.48% ROI-208.30% 52W High-70.89% Beta0.64
Dividend TTM- Quick Ratio0.22 Sales past 5Y12.07% Gross Margin39.65% 52W Low78.46% ATR (14)0.54
Dividend Ex-Date- Current Ratio0.26 EPS Y/Y TTM-19.69% Oper. Margin-104.70% RSI (14)47.76 Volatility14.54% 37.72%
Employees120 Debt/Eq2.42 Sales Y/Y TTM182.02% Profit Margin-264.30% Recom1.00 Target Price25.00
Option/ShortYes / Yes LT Debt/Eq0.95 EPS Q/Q89.07% Payout- Rel Volume0.29 Prev Close2.18
Sales Surprise-42.97% EPS Surprise-70.83% Sales Q/Q312.22% Earnings- Avg Volume1.05M Price2.32
SMA20-15.27% SMA50-6.04% SMA200-28.82% Trades Volume306,880 Change6.42%
Date Action Analyst Rating Change Price Target Change
Jan-30-23Downgrade Morgan Stanley Equal-Weight → Underweight $5 → $1
Dec-22-22Downgrade Oppenheimer Outperform → Perform
Jun-22-22Initiated H.C. Wainwright Buy $15
Apr-06-22Downgrade Truist Buy → Hold $10
Jan-28-22Initiated Oppenheimer Outperform $9
Nov-24-21Initiated Morgan Stanley Equal-Weight $9
Nov-27-24 05:00PM
Nov-20-24 08:30AM
08:30AM
Nov-18-24 08:30AM
Nov-07-24 08:00AM
08:30AM Loading…
Oct-23-24 08:30AM
Oct-22-24 08:30AM
Oct-18-24 06:00PM
Oct-16-24 05:15PM
Sep-05-24 04:05PM
Aug-28-24 04:45PM
Aug-23-24 05:00PM
Jul-31-24 08:30AM
Jun-03-24 08:38AM
May-24-24 05:15PM
09:15AM Loading…
May-14-24 09:15AM
Apr-22-24 08:00AM
Apr-19-24 05:30PM
Apr-18-24 04:30PM
Apr-15-24 08:00AM
Apr-08-24 09:00AM
Mar-26-24 09:00AM
Mar-20-24 09:15AM
Mar-14-24 09:15AM
Mar-12-24 09:20AM
Mar-07-24 09:35AM
Feb-23-24 04:10PM
Feb-14-24 04:05PM
Feb-01-24 09:00AM
Jan-25-24 09:00AM
01:40PM Loading…
Jan-18-24 01:40PM
Jan-04-24 01:00PM
Jan-03-24 07:30PM
12:00PM
Nov-24-23 01:15PM
Oct-18-23 09:00AM
Sep-07-23 04:10PM
Aug-29-23 09:00AM
Jul-27-23 09:07AM
09:00AM
Jul-18-23 09:00AM
Jun-29-23 04:05PM
Jun-01-23 09:15AM
May-23-23 10:56AM
May-19-23 04:21PM
May-10-23 09:00AM
May-01-23 04:01PM
Apr-27-23 09:00AM
Apr-12-23 09:00AM
Apr-05-23 09:00AM
Apr-04-23 09:00AM
Apr-03-23 09:00AM
Mar-28-23 10:55AM
09:00AM
Feb-02-23 07:53AM
Feb-01-23 04:05PM
Jan-26-23 04:17PM
Jan-11-23 01:35PM
01:22PM
Jan-06-23 08:10AM
Jan-04-23 04:10PM
Dec-05-22 08:00AM
Nov-30-22 09:55AM
Nov-10-22 05:00PM
04:10PM
09:10AM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-27-22 08:00AM
Sep-26-22 08:00AM
Sep-15-22 02:29PM
Sep-06-22 04:10PM
Aug-09-22 04:10PM
Jul-27-22 08:00AM
Jul-04-22 10:08AM
Jun-08-22 04:10PM
Jun-03-22 08:00AM
May-18-22 08:30AM
May-16-22 04:10PM
Mar-31-22 04:05PM
Mar-15-22 04:05PM
12:59PM
Feb-15-22 04:05PM
Jan-27-22 05:38PM
05:38PM
Jan-18-22 08:00AM
Dec-27-21 08:00AM
Dec-15-21 09:04AM
Dec-13-21 08:00AM
Nov-29-21 08:00AM
Nov-16-21 05:35AM
Nov-15-21 08:00AM
Nov-12-21 04:05PM
Sep-20-21 08:00AM
08:00AM
Aug-16-21 05:15PM
Aug-04-21 07:00PM
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lim Kok Thay10% OwnerJan 12 '24Buy0.2521,410,9835,331,33551,473,762Jan 17 05:22 PM